{
    "NCT04901455": {
        "brief_title": "Responses to Live Attenuated Influenza Virus (LAIV) in Chronic Obstructive Pulmonary Disease (COPD)",
        "phase": "EARLY_PHASE1",
        "drugs": [
            "LAIV",
            "LAIV",
            "LAIV"
        ],
        "drugs_list": "LAIV, LAIV, LAIV",
        "diseases": [
            "COPD"
        ],
        "diseases_list": "COPD",
        "enrollment": 40,
        "inclusion_criteria": "In order to be eligible to participate in this study, an individual in the COPD group must meet all of the following criteria:\n\n\n\n Age\\>40 years old\n\n\n Physician diagnosis of COPD confirmed by post-bronchodilator testing (defined as forced expiratory volume in one second (FEV1)/forced vital capacity (FVC)\\< lower limit of normal and FEV1/FVC\\<0.70) and FEV1\\>30% predicted at screening\n\n\n Free of acute exacerbation of COPD for prior four weeks at time of recruitment\n\n\n Resting oxygen saturation \\>94 percent\n\n\n Blood pressure systolic values between 90-160 mm Hg and diastolic between 55-90 mm Hg\n\n\n No nasal symptoms based on questionnaire\n\n\n Willingness and ability to participate in study procedures\n\n\n Completion of informed consent\n\nIn order to be eligible to participate in this study, an individual in the healthy control group must meet all of the following criteria:\n\n\n\n Age\\>40 years old\n\n\n Spirometry testing showing normal lung function (defined as pre and post--bronchodilator FEV1/FVC\\>=lower limit of normal and FEV1\\>80 percent predicted) at screening\n\n\n Resting oxygen saturation \\>94 percent\n\n\n Blood pressure systolic values between 90-160 mm Hg and diastolic between 55-90 mm Hg\n\n\n No nasal symptoms based on questionnaire\n\n\n Willingness and ability to participate in study procedures\n\n\n Completion of informed consent",
        "exclusion_criteria": "Inability or unwillingness to consent\n\n\n Active tobacco or e-cigarette use (within last six months)\n\n\n Active diagnosis of asthma\n\n\n Any regular suppressive antibiotics (i.e., azithromycin)\n\n\n Daily oral prednisone use\n\n\n Any supplemental oxygen use beyond nocturnal oxygen therapy\n\n\n Use of intranasal corticosteroids in the 30 days prior to screening visit\n\n\n Chronic illness associated with immunosuppression (i.e., HIV, malignancy)\n\n\n History of documented or self-reported positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection requiring hospitalization\n\n\n Receipt of SARS-CoV-2 vaccine within 14 days prior to study screening visit or plan to receive SARS-CoV-2 vaccine from screening visit to 14 days after completion of all study procedures\n\n\n History of epistaxis, prior nasal surgery or anatomical abnormalities\n\n\n Current use of blood thinner beyond full dose aspirin \\[e.g., warfarin (coumadin), clopidogrel (Plavix), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis)\\]\n\n\n Self-reported history of easy bruising or bleeding gums\n\n\n Serological evidence of HIV infection at screening (Positive HIV antibody test)\n\n\n Relative leukopenia (WBC\\<4000), neutropenia (Absolute neutrophil count\\<2000) or lymphopenia (absolute lymphocyte count\\<1500) on screening CBC\n\n\n Respiratory infection (cough, sore throat, sinusitis, fever) within prior 4 weeks\n\n\n Active wheezing at day 0 visit\n\n\n Pregnancy or nursing or women who are currently trying to become pregnant. (All female subjects, except those who have had a hysterectomy with oophorectomy, will undergo urine pregnancy testing on the morning of the screening visit and again on the on Day 0 at the time of arrival to the lab and prior to LAIV administration. A positive pregnancy test will exclude the subject)\n\n\n Use of chronic immunosuppression in the 30 days prior to screening visit\n\n\n History of hypersensitivity, especially anaphylactic reactions, to egg proteins, gentamicin, gelatin, or arginine, or with a reaction to previous influenza vaccination at a severity level precluding the subject's participation as judged by the study physician\n\n\n History of Guillain-Barre syndrome\n\n\n Subjects who will be unable to avoid contact with immunocompromised individuals for 3 weeks after receiving LAIV vaccine\n\n\n Receipt of the LAIV during the current or prior flu vaccine season\n\n\n Physician diagnosed influenza, a positive test for influenza or suspicion of influenza illness in the 18 months prior to enrollment. Suspicion of influenza will be based on the CDC's influenza-like illness case definition (\"fever\\>100 \u00b0F AND cough/sore throat in the absence of a known cause other than influenza. Temperature can be measured in the office or at the home\")\n\n\n Any condition that, in the opinion of the study investigator, would compromise the subject's ability to participate in the study",
        "brief_summary": "This study will determine the functional status of the nasal immune environment with LAIV exposure in COPD persons with frequent exacerbations (defined as individuals with two or more episodes of worsening in COPD symptoms requiring treatment with antibiotics and/or steroids in the prior 12 months) and COPD persons without frequent exacerbations to determine acute exacerbation of COPD (AECOPD)-associated dysfunction in a) cytokines and immune effector cells of the nasal mucosa and b) viral replication. The investigators hypothesize that: 1) COPD frequent exacerbators, compared to COPD infrequent exacerbators, will demonstrate altered mucosal immune responses to LAIV exposure, and 2) COPD frequent exacerbators, compared to COPD infrequent exacerbators, will demonstrate increased markers of influenza viral replication after LAIV exposure.",
        "NCTID": "NCT04901455"
    },
    "NCT05166889": {
        "brief_title": "Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations",
        "phase": "PHASE3",
        "drugs": [
            "Tozorakimab",
            "Tozorakimab",
            "Placebo"
        ],
        "drugs_list": "Tozorakimab, Tozorakimab, Placebo",
        "diseases": [
            "Chronic Obstructive Pulmonary Disease (COPD)"
        ],
        "diseases_list": "Chronic Obstructive Pulmonary Disease (COPD)",
        "enrollment": 1099,
        "inclusion_criteria": "1. Participant must be \u2265 40 years of age and capable of giving signed informed consent.\n2. Documented diagnosis of COPD for at least one year prior to enrolment.\n3. Post BD FEV1/FVC \\< 0.70 and post-BD FEV1 \\>20% of predicted normal value.\n4. Documented history of \u2265 2 moderate or \u2265 1 severe COPD exacerbations within 12 months prior to enrolment.\n5. Documented optimized inhaled dual or triple therapy at a stable dose for at least 3 months prior to enrolment.\n6. Smoking history of \u2265 10 pack-years.\n7. CAT total score \u226510, with each of the phlegm (sputum) and cough items with a score \u2265 2.",
        "exclusion_criteria": "1. Clinically important pulmonary disease other than COPD.\n2. Radiological findings suggestive of a respiratory disease other than COPD that is significantly contributing to the participant's respiratory symptoms.\n3. Current diagnosis of asthma, prior history of asthma, or asthma-COPD overlap. Childhood history of asthma is allowed and defined as asthma diagnosed and resolved before the age of 18.\n4. Any unstable disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric disorder, major physical and/or cognitive impairment that could affect safety, study findings or participants ability to complete the study.\n5. COPD exacerbation, within 2 weeks prior to randomization, that was treated with systemic corticosteroids and/or antibiotics, and/or led to hospitalization.\n6. Active significant infection within the 4 weeks prior to randomization, pneumonia within 6 weeks prior to randomization, or medical condition that predisposes the participant to infection.\n7. Suspicion of, or confirmed, ongoing SARS-CoV-2 infection.\n8. Significant COVID-19 illness within the 6 months prior to enrolment.\n9. Unstable cardiovascular disorder.\n10. Diagnosis of cor pulmonale, pulmonary arterial hypertension and/or right ventricular failure.\n11. History of known immunodeficiency disorder, including a positive test for HIV-1 or HIV 2.\n12. History of positive test or treatment for hepatitis B or hepatitis C (except for cured hepatitis C)\n13. Evidence of active liver disease, including jaundice during screening.\n14. Malignancy, current or within the past 5 years, except for adequately treated non-invasive basal cell and squamous cell carcinoma of the skin and cervical carcinoma-in-situ treated with apparent success more than one year prior to enrolment. Suspected malignancy or undefined neoplasms.\n15. Participants who have evidence of active TB.\n16. Participants that have previously received tozorakimab.\n17. Any clinically significant abnormal findings in physical examination, vital signs, ECG, or laboratory testing during the screening period, which in the opinion of the investigator may put the participant at risk because of their participation in the study, or may influence the results of the study, or the participant's ability to complete the entire duration of the study.\n18. Active vaping of any products or using smoked marijuana within the 6 months prior to randomization and during the study.",
        "brief_summary": "The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab Dose 1 and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic COPD and history of \u2265 2 moderate or \u2265 1 severe exacerbation of COPD in the previous 12 months. Participants should be receiving optimised treatment with maintenance inhaled therapy (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate) in stable doses throughout at least 3 months prior to enrolment.",
        "NCTID": "NCT05166889"
    },
    "NCT05742802": {
        "brief_title": "Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).",
        "phase": "PHASE3",
        "drugs": [],
        "drugs_list": "",
        "diseases": [
            "Chronic Obstructive Pulmonary Disease (COPD)"
        ],
        "diseases_list": "Chronic Obstructive Pulmonary Disease (COPD)",
        "enrollment": 1869,
        "inclusion_criteria": "1. Participants who have completed the treatment period and have not been prematurely discontinued from IP in the predecessor studies.\n2. Participants who received their last dose of IP in the predecessor studies within the previous 12 weeks and were not withdrawn from the predecessor study.\n3. FOCBP (female(s) of childbearing potential) must have a negative urine pregnancy test at Visit 1.\n4. Participants who are willing to continue using contraceptive methods as agreed to for the predecessor OBERON or TITANIA studies.\n5. Capable of giving signed informed consent.",
        "exclusion_criteria": "1. Any clinically significant disorder or abnormal findings (clinical, laboratory, instrumental, etc) or major physical and/or cognitive impairment - which, in the opinion of the Investigator, may put the participant at risk because of his/her participation in the study or impact the interpretation of the study results, or otherwise make the participation of the participant inappropriate.\n2. Participant meeting criteria for IP discontinuation as judged by the Investigator or the Sponsor.\n3. Concurrent enrolment in other interventional clinical studies or treatment with another IP, with the exception of the OBERON and TITANIA predecessor studies.\n4. Known history of:\n\n   1. Severe allergic reaction to any monoclonal and polyclonal antibody.\n   2. Allergy or reaction to any component of the IP formulation.\n5. Chronic use (or expected need for chronic use during the study) of immunosuppressive medications (including, but not limited to, systemic corticosteroids), marketed or investigational biologic, or another prohibited medication.\n6. Involvement in the planning and/or conduct of the study (applies to both staff employed by the Sponsor and/or staff at the study site).\n7. Participants who are not able to comply with the study requirements, procedures, and restrictions.",
        "brief_summary": "Subjects who completed either OBERON or TITANIA will be offered the opportunity to consent for this Multicentre, Double-blind, Randomised, Placebo controlled, Parallel Group, Phase 3, extension study to evaluate the safety and efficacy of Tozorakimab in adult participants with symptomatic COPD.",
        "NCTID": "NCT05742802"
    },
    "NCT04069312": {
        "brief_title": "Roflumilast or Azithromycin to Prevent COPD Exacerbations (RELIANCE)",
        "phase": "PHASE4",
        "drugs": [
            "Roflumilast",
            "Azithromycin"
        ],
        "drugs_list": "Roflumilast, Azithromycin",
        "diseases": [
            "Chronic Obstructive Pulmonary Disease Severe",
            "Chronic Bronchitis"
        ],
        "diseases_list": "Chronic Obstructive Pulmonary Disease Severe, Chronic Bronchitis",
        "enrollment": 1250,
        "inclusion_criteria": "Patient and treating clinician considering treatment intensification with roflumilast or azithromycin to reduce the risk of COPD exacerbations\n\n\n Age \u2265 40 years\n\n\n Current or past smoker of at least 10 pack-years\n\n\n Diagnosis of severe COPD and associated chronic bronchitis\n\n\n Hospitalized with a diagnosis of COPD exacerbation or respiratory complications due to COVID 19 in the past 12 months\n\n\n Current medications include inhaled Long Acting Muscarinic Antagonist (LAMA), Long Acting Beta Agonist (LABA) /LAMA, or Inhaled Corticosteroids (ICS) /LABA\n\n\n English or Spanish speaking",
        "exclusion_criteria": "Unable or declines to provide informed consent;\n\n\n Declines to provide social security number or health insurance claims number (as applicable)\n\n\n History of intolerance to azithromycin or roflumilast that the patient or patient's treating clinician considers sufficiently serious to avoid either treatment option;\n\n\n Current treatment with long-term (more than 30 days) roflumilast or azithromycin (previous treatment with 1 or more doses of azithromycin or roflumilast is not an exclusion criterion, as long as the patient and clinician are seeking treatment intensification options and would be willing to use azithromycin or roflumilast, as per randomized treatment assignment.)\n\n\n Known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide antibiotic;\n\n\n History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin\n\n\n Moderate to severe liver impairment (Child-Pugh B or C)\n\n\n Current pregnancy\n\n\n Any other clinician-determined exclusion as per the clinician's clinical practice",
        "brief_summary": "A multi-center, randomized, 72-month, parallel- group, non-inferiority, phase III study to compare the effectiveness of roflumilast (Daliresp, 500 mcg quaque die (QD) or alternate regimen) therapy versus azithromycin (250 mg QD, 500 mg QD three times per week, or alternate regimen) to prevent hospitalization or death in a patients at high risk for COPD exacerbations.",
        "NCTID": "NCT04069312"
    },
    "NCT06075095": {
        "brief_title": "A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a New Propellant (HFO) in Participants 40 to 80 Years of Age With COPD",
        "phase": "PHASE3",
        "drugs": [
            "BGF MDI HFO 320/14.4/9.6\u03bcg",
            "BGF MDI HFA 320/14.4/9.6 \u03bcg",
            "Placebo MDI HFA",
            "BGF MDI HFO 320/14.4/9.6\u03bcg",
            "BGF MDI HFA 320/14.4/9.6 \u03bcg",
            "Placebo MDI HFA",
            "BGF MDI HFO 320/14.4/9.6\u03bcg",
            "BGF MDI HFA 320/14.4/9.6 \u03bcg",
            "Placebo MDI HFA",
            "BGF MDI HFO 320/14.4/9.6\u03bcg",
            "BGF MDI HFA 320/14.4/9.6 \u03bcg",
            "Placebo MDI HFA",
            "BGF MDI HFO 320/14.4/9.6\u03bcg",
            "BGF MDI HFA 320/14.4/9.6 \u03bcg",
            "Placebo MDI HFA",
            "BGF MDI HFO 320/14.4/9.6\u03bcg",
            "BGF MDI HFA 320/14.4/9.6 \u03bcg",
            "Placebo MDI HFA"
        ],
        "drugs_list": "BGF MDI HFO 320/14.4/9.6\u03bcg, BGF MDI HFA 320/14.4/9.6 \u03bcg, Placebo MDI HFA, BGF MDI HFO 320/14.4/9.6\u03bcg, BGF MDI HFA 320/14.4/9.6 \u03bcg, Placebo MDI HFA, BGF MDI HFO 320/14.4/9.6\u03bcg, BGF MDI HFA 320/14.4/9.6 \u03bcg, Placebo MDI HFA, BGF MDI HFO 320/14.4/9.6\u03bcg, BGF MDI HFA 320/14.4/9.6 \u03bcg, Placebo MDI HFA, BGF MDI HFO 320/14.4/9.6\u03bcg, BGF MDI HFA 320/14.4/9.6 \u03bcg, Placebo MDI HFA, BGF MDI HFO 320/14.4/9.6\u03bcg, BGF MDI HFA 320/14.4/9.6 \u03bcg, Placebo MDI HFA",
        "diseases": [
            "COPD (Chronic Obstructive Pulmonary Disease)"
        ],
        "diseases_list": "COPD (Chronic Obstructive Pulmonary Disease)",
        "enrollment": 255,
        "inclusion_criteria": "Participants are eligible to be included in the study only if all of the following criteria apply:\n\nAge\n\n1. Participants must be 40 to 80 years inclusive at the time of signing the ICF. Type of Participant and Disease Characteristics\n2. Participants who have a documented history of physician-diagnosed COPD as defined by the ATS/ERS (Celli et al 2004).\n3. Participants who have been receiving LABA, LAMA, LAMA/LABA, or ICS/LABA inhaled maintenance therapies for the management of their COPD for at least 4 weeks prior to Visit 1, OR Participants who have been receiving SABA, SAMA, or SABA/SAMA either scheduled or as needed for at least 4 weeks prior to Visit 1, OR Participants who are COPD treatment-na\u00efve or have not received previously prescribed COPD treatment in the 4 weeks prior to Visit 1.\n4. At Visit 1: Participants with a blood eosinophil count \\< 300 cells/\u03bcL.\n5. At Visit 1: Participants with a pre-bronchodilator FEV1 of \\< 80% predicted normal.\n6. At Visit 2: Participants with a post-bronchodilator FEV1/FVC ratio of \\< 0.70 and a postbronchodilator FEV1 of \u2265 40% to \\< 80% predicted normal.\n7. At Visit 3 (TP 1 Day 1): Participants with a pre-dose FEV1 of \\< 80% predicted normal that is within \u00b1 20% or 200 mL of their Visit 2 pre-bronchodilator FEV1 and an FEV1/FVC ratio of \\< 0.70.\n8. Current or former smokers with a history of at least 10 pack-years of tobacco smoking\n\n<!-- -->\n\n1. pack-year = 20 cigarettes smoked per day for one year). 9 Participants who are willing and, in the opinion of the Investigator, able to adjust current COPD therapy, as required by the protocol. Sex and Contraceptive/Barrier Requirements 10 Females must not be of childbearing potential or must use a form of highly effective birth control as defined below:\n\n   \n\n Females not of childbearing potential are defined as females who are either permanently sterilised (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy) or postmenopausal. Females will be considered postmenopausal if they have been amenorrhoeic for 52 weeks (12 months) prior to the planned date of randomisation without an alternative medical cause. The following age-specific requirements apply:\n\n     \n\n Females \\< 50 years old would be considered postmenopausal if they have been amenorrhoeic for 52 weeks (12 months) or more following cessation of exogenous hormonal treatment with FSH levels in the postmenopausal range.\n     \n\n Females \u2265 50 years old would be considered postmenopausal if they have been amenorrhoeic for 52 weeks (12 months) or more following cessation of all exogenous hormonal treatment.\n   \n\n Female participants of childbearing potential must use one highly effective form of birth control. A highly effective method of contraception is defined as one that can achieve a failure rate of less than 1% per year when used consistently and correctly.\n\n   All FOCBP who are sexually active with a non-sterilised male partner must agree to use one highly effective method of birth control, as defined below, from enrolment throughout the study and until at least 14 days after the last dose of study intervention. Cessation of contraception after this point should be discussed with a responsible physician. Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational \\[15:32\\] \u0141ubian, Dominika amenorrhoea method are not acceptable methods of contraception. Female condom and male condom should not be used together.\n\n   - All FOCBP must have a negative serum pregnancy test result at Visit 1.\n\n   - Females \\< 50 years of age with amenorrhoea for at least 12 months without an alternative medical cause must have a serum FSH test at Visit 1.\n   \n\n Highly effective birth control methods are listed below:\n\n     - Total sexual abstinence is an acceptable method provided it is the preferred and usual lifestyle of the participant (defined as refraining from heterosexual intercourse during the entire period of risk associated with the study interventions).\n\n     - Combined (oestrogen and progestogen-containing) hormonal contraception associated with inhibition of ovulation:\n\n     o Oral\n\n     o Intravaginal\n\n     o Transdermal\n     \n\n Progestogen-only hormonal contraception associated with inhibition of ovulation: o Oral\n\n       o Injectable\n       \n\n Implantable\n     \n\n Intrauterine device (IUD) or intrauterine hormone-releasing system (IUS)\n     \n\n Bilateral tubal occlusion\n     \n\n Male partner sterilisation/vasectomy with documentation of azoospermia prior to the female participant's entry into the study, and this male is the sole partner for that participant. The documentation on male sterility can come from the site personnel's review of participant's medical records, medical examination and/or semen analysis or medical history interview provided by her or her partner. Informed Consent 11 Capable of giving signed informed consent as described in Appendix A which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.\n\n   Other Inclusion Criteria 12 Participants with calculated eGFR \\> 30 mL/min/1.73 m2 using the CKD-EPI formula.\n\n13 Participants who demonstrate acceptable MDI administration and spirometry techniques.\n\n14 Participants who remain compliant with placebo run-in administrations, defined as \u2265 80% of planned doses over the last 7 days prior to Visit 3, based on ePRO diary data.\n\n15 Participants who are willing to remain at the study centre as required per protocol to complete all visit assessments.",
        "exclusion_criteria": "Medical Conditions\n\n1. Confirmed diagnosis of asthma, in the opinion of the Investigator based on thorough review of medical history and medical records.\n2. COPD due to \u03b11-antitrypsin deficiency.\n3. A COPD exacerbation treated with systemic corticosteroids or antibiotics within 4 months prior to Visit 1 or during the Screening Period.\n4. A COPD exacerbation that required hospitalisation within 12 months prior to Visit 1 or during the Screening Period.\n5. A respiratory infection ending within 4 weeks prior to Visit 1 or beginning or ending during the Screening Period, per the Investigator's judgement.\n6. Life-threatening COPD (eg, need for mechanical ventilation) at any time prior to Visit 1 or during the Screening Period.\n7. A SARS-CoV-2 infection in the 8 weeks prior to Visit 1 or during the Screening Period, or that required hospitalisation at any time prior to Visit 1 or during the Screening Period.\n8. Sleep apnoea that, in the opinion of the Investigator, is uncontrolled.\n9. Other respiratory disorders including, but not limited to, known active tuberculosis, lung cancer, cystic fibrosis, significant bronchiectasis (high-resolution CT evidence of bronchiectasis that causes repeated acute exacerbations), severe neurological disorders affecting control of the upper airway, sarcoidosis, primary ciliary dyskinesia, idiopathic interstitial pulmonary fibrosis, primary pulmonary hypertension, or pulmonary thromboembolic disease.\n10. Significant or unstable ischaemic heart disease, arrhythmia, cardiomyopathy, heart failure, uncontrolled hypertension as defined by the Investigator, or any other relevant cardiovascular disorder as judged by the Investigator.\n11. Diagnosis of narrow-angle glaucoma that has not been adequately treated, or a change in vision that may be relevant, in the opinion of the Investigator.\n\n    Note: All medications approved for control of intraocular pressures are allowed, including topical ophthalmic nonselective beta-blockers and prostaglandin analogues.\n12. Symptomatic prostatic hypertrophy or bladder neck obstruction/urinary retention that, in the opinion of the Investigator, is clinically significant.\n13. Unresectable cancer that has not been in complete remission for at least 5 years prior to Visit 1. Note: Squamous cell and basal cell carcinomas of the skin are allowed.\n14. Historical or current evidence of a clinically significant disease including, but not limited to: cardiovascular, hepatic, renal, haematological, neurological, endocrine, gastrointestinal, or pulmonary. Immune deficiency disorders (ie, HIV infection) should be excluded even if controlled. Significant is defined as any disease that, in the opinion of the Investigator, would put the safety of the participant at risk through participation, or that could affect the efficacy or safety analysis if the disease/condition is exacerbated during the study.\n15. Participants with a known hypersensitivity to beta2-agonists, muscarinic antagonists, or corticosteroids, or any component of the MDI.\n16. Known history of drug or alcohol abuse within 12 months of Visit 1 or known abuse at any time during the study.\n17. History of QT prolongation associated with another medication that required discontinuation of that medication.\n\n    Prior/Concomitant Therapy\n18. Unable to abstain from short-acting bronchodilators within 6 hours prior to lung function testing at each study visit.\n19. Pulmonary resection or lung volume reduction surgery during the 6 months prior to Visit 1 (ie, lobectomy, bronchoscopic lung volume reduction \\[endobronchial blockers, airway bypass, endobronchial valves, thermal vapour ablation, biological sealants, and airway implants\\]).\n20. Long-term-oxygen therapy or nocturnal oxygen therapy required for greater than 15 hours per day.\n\n    Note: As-needed oxygen use is allowed.\n21. Trans-urethral resection of the prostate or full resection of the prostate within 6 months prior to Visit 1.\n22. Unable to abstain from any protocol-defined prohibited medications during the Screening or Treatment Periods (see Section 6.9).\n23. Use of any herbal products by either inhalation or nebuliser within 2 weeks prior to Visit 1 or refusal to stop use for the duration of the study.\n\n    Prior/Concurrent Clinical Study Experience\n24. Participation in another clinical study with a study intervention administered within 30 days or 5 half-lives, whichever is longer, prior to Visit 1.\n\n    Diagnostic Assessments\n25. Participants with ECG QTcF interval \\> 480 milliseconds.\n26. Participants with high-degree atrioventricular block II or III, or with sinus node dysfunction with clinically significant pauses who are not treated with pacemaker.\n27. Any clinically relevant abnormal findings in physical examination, clinical chemistry, haematology, urinalysis, vital signs, or ECG which, in the opinion of the Investigator, may put the participant at risk because of their participation in the study.\n\n    Other Exclusions\n28. Planned hospitalisation during the study.\n29. Involvement in the planning or conduct of the study (applies to both AstraZeneca staff and staff at the study sites).\n30. Study Investigators, sub-Investigators, coordinators, and their employees or immediate family members.\n31. Judgement by the Investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.\n32. Previous randomisation in the present study.\n33. For women only: currently pregnant (confirmed with positive pregnancy test), breastfeeding, or planned pregnancy during the study, or FOCBP not using acceptable contraception measures.",
        "brief_summary": "The purpose of this study is to demonstrate that the lung function effect from orally inhaled BGF delivered via HFO propellant is equivalent to the lung function effect from orally inhaled BGF delivered via HFA propellant in participants with COPD. The study duration for each participant will be approximately 15 to 16 weeks and consist of:\n\n1. A screening and placebo run-in period of approximately 2 weeks prior to first dosing\n2. Three treatment periods of approximately 4 weeks each (one period for each of 3 study interventions)\n3. A final safety follow-up visit via telephone contact approximately 1 to 2 weeks after the final dose administration Participants will be provided with rescue SABA (albuterol or salbutamol) to be used as needed throughout the study. Participants will attend in-clinic study visits approximately weekly during the screening/run-in period (Visits 1, 2, and 3), then every 4 weeks (Visits 4, 5, and 6) to receive take-home study treatment, measure their lung function, and assess their health and safety",
        "NCTID": "NCT06075095"
    },
    "NCT05878769": {
        "brief_title": "A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)",
        "phase": "PHASE3",
        "drugs": [
            "Astegolimab"
        ],
        "drugs_list": "Astegolimab",
        "diseases": [
            "Chronic Obstructive Pulmonary Disease"
        ],
        "diseases_list": "Chronic Obstructive Pulmonary Disease",
        "enrollment": 2000,
        "inclusion_criteria": "Completion of the 52-week treatment period in either parent GB43311 or GB44332",
        "exclusion_criteria": "Withdrawal of consent and/or premature discontinuation from parent study\n\n\n Any permanent discontinuation of study drug in parent study\n\n\n Significant non-compliance in the parent study, specifically defined as missing scheduled visits, per investigator's judgment\n\n\n Any new diagnosis of asthma according to the Global Initiative for Asthma guidelines or other accepted guidelines since enrolling in the parent study\n\n\n Any new clinically significant pulmonary disease other than COPD (e.g., pulmonary fibrosis, sarcoidosis, chronic pulmonary embolism or primary pulmonary hypertension, alpha-1-antitrypsin deficiency) since enrolling in the parent study\n\n\n Any new unstable cardiac disease, myocardial infarction, or New York Heart Association Class III or IV heart failure since enrolling in the parent study",
        "brief_summary": "The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment period in parent studies GB43311 or GB44332.",
        "NCTID": "NCT05878769"
    },
    "NCT05612035": {
        "brief_title": "MK-5475-013 INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of MK-5475 (an Inhaled sGC Stimulator) in Adults With PH-COPD",
        "phase": "PHASE2",
        "drugs": [
            "MK-5475",
            "MK-5475",
            "Placebo"
        ],
        "drugs_list": "MK-5475, MK-5475, Placebo",
        "diseases": [
            "Pulmonary Hypertension",
            "Chronic Obstructive Pulmonary Disease"
        ],
        "diseases_list": "Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease",
        "enrollment": 120,
        "inclusion_criteria": "The key inclusion and exclusion criteria include but are not limited to the following:\n\n\n\n\n\n Has Group 3.1 pulmonary hypertension chronic obstructive pulmonary disease (PH-COPD) as defined by the Clinical Classification of Pulmonary Hypertension.\n\n\n Has a right heart catheterization (RHC) at screening or historical RHC within 12 months before screening that meets hemodynamic criteria.\n\n\n Has a physician diagnosis of obstructive lung disease on pulmonary function testing (PFT) performed at screening.\n\n\n Has a WHO Functional Class assessment of Class II to IV.\n\n\n If on supplemental oxygen, the regimen must be stable.\n\n\n Has stable and optimized chronic, baseline COPD-specific therapy.\n\n\n If on PDE5 inhibitor, has stable concomitant use (initiated at least 3 months prior to randomization and no change in drug or dosage for at least 3 months prior to randomization) and changes to PDE5 inhibitor dosing is not anticipated during the 24 week Base Period.\n\n\n If on antihypertensives and/or a diuretic regimen has stable concomitant use.\n\n\n If on anticoagulants has stable concomitant use.\n\n\n Is of any sex/gender from 40 to 85 years of age inclusive.\n\n\n Female is not pregnant or breastfeeding, and is not of childbearing potential or uses acceptable contraceptive method or abstains from sexual intercourse, or has a negative highly sensitive pregnancy test within 24 hours before the first dose of study intervention, or whose history and sexual activity has been reviewed by the investigator.\n\nExclusion criteria:\n\n\n\n Has Group 1 pulmonary arterial hypertension (PAH), Groups 2, 4 or 5 pulmonary hypertension (PH).\n\n\n Has non-COPD related Group 3 PH.\n\n\n Has evidence of untreated more than mild obstructive sleep apnea.\n\n\n Has significant left heart disease.\n\n\n Expects to receive a lung and/or heart transplant from screening through the end of the 24 week Base Period.\n\n\n Has evidence of a resting oxygen saturation (SpO2) \\< 88%.\n\n\n Has experienced a moderate or severe COPD exacerbation within 2 months before randomization.\n\n\n Has experienced right heart failure within 2 months before randomization.\n\n\n Has uncontrolled tachyarrhythmia.\n\n\n Has acute coronary syndrome, undergone coronary artery bypass graft, or percutaneous coronary intervention within 2 months before randomization.\n\n\n Has evidence of significant chronic renal insufficiency.\n\n\n Has evidence of chronic liver disease, portal hypertension, cirrhosis, or hepatic abnormalities.\n\n\n Initiated a pulmonary rehabilitation program within 2 months before randomization.\n\n\n Has impairments that limit the ability to perform 6MWT.\n\n\n Has history of cancer.\n\n\n Is a user of illicit drugs or has a recent history of drug/alcohol abuse or dependence.\n\n\n Has used PAH-specific therapies within 2 months of randomization.",
        "exclusion_criteria": "No Exclusion Criteria",
        "brief_summary": "Researchers are looking for ways to treat pulmonary hypertension (PH) caused by chronic obstructive pulmonary disease (COPD). The goal of the study is to learn if people who take MK-5475 can walk farther in 6 minutes at Week 24 compared to people who take placebo.",
        "NCTID": "NCT05612035"
    },
    "NCT04778046": {
        "brief_title": "Pulmonary Hypertension SOLAR",
        "phase": "PHASE2",
        "drugs": [
            "Hyperpolarized 129Xe",
            "Hyperpolarized 129Xe",
            "Hyperpolarized 129Xe",
            "Hyperpolarized 129Xe",
            "Hyperpolarized 129Xe"
        ],
        "drugs_list": "Hyperpolarized 129Xe, Hyperpolarized 129Xe, Hyperpolarized 129Xe, Hyperpolarized 129Xe, Hyperpolarized 129Xe",
        "diseases": [
            "Interstitial Lung Disease",
            "COPD",
            "Pulmonary Arterial Hypertension"
        ],
        "diseases_list": "Interstitial Lung Disease, COPD, Pulmonary Arterial Hypertension",
        "enrollment": 30,
        "inclusion_criteria": "1. Age \u2265 18 years' old\n2. Be on the lung transplant waiting list at Duke University Medical Center.\n3. PH as defined by RHC - mPAP \\> 20 mmHg, PVR \\> 3 WU, PCWP \\< 15 mmHg\n4. Groups defined as:\n\n   PAH: Clinical diagnosis of PAH (Group 1 PH) in the absence of severe chronic lung disease, left heart disease, chronic thromboembolism, sarcoidosis, sickle cell disease, or other causes of non-Group 1 PH.\n\n   COPD-noPH: Clinical diagnosis of COPD in the absence of precapillary PH.\n\n   COPD-PH: Clinical diagnosis of COPD with precapillary PH.\n\n   IPF-noPH: Clinical diagnosis of IPF in the absence of precapillary PH.\n\n   IPF-PH: Clinical diagnosis of IPF with precapillary PH.\n5. Willing and able to give informed consent and adhere to visit/protocol schedules (consent must be given before any study procedures are performed).",
        "exclusion_criteria": "1. Moderate to severe heart disease (LVEF \\< 45% or severe LV Hypertrophy).\n2. Sarcoidosis.\n3. Active cancer.\n4. Sickle cell anemia.\n5. Liver disease (Childs-Pugh class C).\n6. Prisoners and pregnant women will not be approached for the study.\n7. Inability to obtain consent.\n8. Conditions that will prohibit MRI scanning (metal in eye, claustrophobia, inability to lie supine).\n9. Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements",
        "brief_summary": "The main goal of this study is to develop a noninvasive signature for pulmonary vascular remodeling in Group 3 PH patients, using hyperpolarized 129Xe magnetic resonance imaging (129Xe MRI). Such a signature may identify Group 3 PH responders to PAH-specific therapies. PAH's unique 129Xe MRI signature has been shown in previous studies. Past studies have lacked a pathologic \"ground truth\" correlate of these signatures, which could be provided by comparing them with the pathology of lung explant tissue from patients who have undergone a lung transplant. This signature could be validated in a cohort of patients with Group 3 PH in future studies.",
        "NCTID": "NCT04778046"
    },
    "NCT05595642": {
        "brief_title": "A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease",
        "phase": "PHASE3",
        "drugs": [
            "Astegolimab",
            "Astegolimab",
            "Placebo"
        ],
        "drugs_list": "Astegolimab, Astegolimab, Placebo",
        "diseases": [
            "Chronic Obstructive Pulmonary Disease (COPD)"
        ],
        "diseases_list": "Chronic Obstructive Pulmonary Disease (COPD)",
        "enrollment": 1290,
        "inclusion_criteria": "Inclusion Criteria\n\n\n\n Documented COPD diagnosis for \u2265 12 months\n\n\n History of frequent exacerbations, defined as having had 2 or more moderate or severe COPD exacerbations within 12 months prior to screening\n\n\n Post-bronchodilator FEV1 \u2265 20% and \\< 80% of predicted at screening\n\n\n Post-bronchodilator FEV1/FVC \\< 0.70 at screening\n\n\n Modified Medical Research Council (dyspnea scale) (mMRC) score \u2265 2\n\n\n Current tobacco smoker or former smoker with a history of smoking \u2265 10 pack-years\n\n\n On optimized COPD maintenance therapy as defined below for \u2265 12 months prior to screening, and stable on current therapy for at least 4 weeks prior to screening: Inhaled corticosteroid (ICS) plus long-acting beta-agonist (LABA), Long-acting muscarinic antagonist (LAMA) plus LABA, ICS plus LAMA plus LABA\n\n\n Chest X-ray or computed tomography (CT) scan within 6 months prior to screening or chest X-ray during the screening period that confirms the absence of clinically significant lung disease besides COPD\n\nExclusion Criteria\n\n\n\n Current documented diagnosis of asthma\n\n\n History of clinically significant pulmonary disease other than COPD\n\n\n Diagnosis of 1-antitrypsin deficiency\n\n\n History of long-term treatment with oxygen at \\> 4.0 liters/minute\n\n\n Lung volume reduction surgery or procedure within 12 months prior to screening\n\n\n Individuals participating in, or scheduled for, an intensive COPD rehabilitation program (participants who are in the maintenance phase of a rehabilitation program are eligible)\n\n\n History of lung transplant\n\n\n Any infection that resulted in hospital admission for \u2265 24 hours and/or treatment with oral, IV, or IM antibiotics within 4 weeks prior to or during screening\n\n\n Upper or lower respiratory tract infection within 4 weeks prior to or during screening\n\n\n Treatment with oral, IV, or IM corticosteroids within 4 weeks prior to initiation of study drug\n\n\n Initiation of or change in non-biologic immunomodulatory or immunosuppressive therapy within 3 months prior to screening\n\n\n Unstable cardiac disease, myocardial infarction, or New York Heart Association Class III or IV heart failure within 12 months prior to screening",
        "exclusion_criteria": "No Exclusion Criteria",
        "brief_summary": "This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COPD) who are former or current smokers and have a history of frequent exacerbations.",
        "NCTID": "NCT05595642"
    },
    "NCT06283966": {
        "brief_title": "A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease",
        "phase": "PHASE3",
        "drugs": [
            "BGF MDI 320/14.4/9.6 \u03bcg",
            "GFF MDI 14.4/9.6 \u03bcg"
        ],
        "drugs_list": "BGF MDI 320/14.4/9.6 \u03bcg, GFF MDI 14.4/9.6 \u03bcg",
        "diseases": [
            "COPD (Chronic Obstructive Pulmonary Disease)"
        ],
        "diseases_list": "COPD (Chronic Obstructive Pulmonary Disease)",
        "enrollment": 5000,
        "inclusion_criteria": "1. Male or female participants must be 40 to 80 years of age inclusive, at the time of signing\n\n   the ICF.\n2. Demonstrate acceptable MDI administration technique at Visit 1 (V1) and Visit 2 (V2)\n3. A diagnosis of COPD confirmed by a post-bronchodilator FEV1/FVC ratio \\< 70%\n\n   at V1.\n4. Current or former smokers with a history of at least 10 pack-years of cigarette smoking;\n\n   defined as (number of cigarettes per day/20) x number of years smoked. Previous smokers are defined as those who have stopped smoking for at least 6\n\n   months prior to V1.\n5. A baseline peripheral blood eosinophil count of \u2265 100 cells/mm3 assessed at Visit 1 by\n\n   the central laboratory\n6. A CAT score of \u2265 10 at Visit 1.\n7. Participant must fulfill at least 1 of the 4 CV disease/risk factor criteria below \\[(a), (b),\n\n   (c), or (d)\\]:\n   1. : Established CV Disease\n   2. : Combination of CV risk factors:\n\n      \n\n Hypertension\n      \n\n Diabetes Mellitus\n      \n\n Chronic Kidney Disease\n      \n\n Dyslipidemia\n      \n\n Obesity\n   3. : High risk of CV disease determined using an established CV risk assessment\n\n      tool.\n   4. : CT coronary Artery Calcification\n8. Willing and, in the opinion of the investigator, able to adjust current COPD therapy, as\n\n   required by the protocol.\n9. Willing to visit at the study site or participate in virtual visits as required per the protocol\n\n   to complete all study assessments.\n10. A female is eligible to enter and participate in the study if the female is of:\n\n    \n\n Non-childbearing potential: either permanently sterilized or who are post-menopausal.\n    \n\n Childbearing potential: has a negative serum pregnancy test at V1 and must use one\n\n    highly effective form of birth control.\n11. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in the protocol.",
        "exclusion_criteria": "1. Active diagnosis of asthma within the past 5 years (previous diagnosis as a child or adolescent are eligible), asthma-COPD overlap, or any other chronic respiratory disease other than COPD such as alpha-1 antitrypsin deficiency, active tuberculosis, lung fibrosis, sarcoidosis, interstitial lung disease, and pulmonary hypertension.\n2. End-stage renal disease requiring renal replacement therapy\n3. History of heart or lung transplant or actively listed for heart or lung transplant.\n4. Implanted left ventricular assist device or implant anticipated in \\< 3 months.\n5. History of lung cancer and/or treatment for lung cancer within the 5 years prior to Visit 1.\n6. Unstable or life-threatening cardiac disease - participants with any of the following at Visit 1 would be excluded:\n\n   1. An MI or unstable angina in the last 8 weeks\n   2. Unstable or life-threatening cardiac arrhythmia requiring intervention in the last 8 weeks.\n\n   NOTE: Any participant who experiences unstable or life-threatening cardiac disease during the run-in period will be excluded but can be rescreened 8 weeks after the resolution of the event.\n7. Pneumonia and/or moderate or severe COPD exacerbation that has not resolved at least 8 weeks prior to Visit 1\n8. Any life-threatening condition, including malignancy, with a life expectancy \\< 5 years, other than CV disease or COPD, that might prevent the participant from completing the study.\n9. Use of maintenance ICS treatment within the past 12 months.\n10. Unable to abstain from protocol-defined prohibited medications\n11. Participation in another clinical study with a study intervention administered in the last 30 days or 5 half-lives, whichever is longer prior to Visit 1 (any other investigational product that is not identified in protocol is prohibited for use during the duration of the study).\n12. Participants with a known hypersensitivity to LAMA, LABA or ICS or any component of the MDI.\n13. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).\n14. Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.\n15. Previous randomization in the present study.\n16. For females only - currently pregnant (confirmed with positive pregnancy test) or breastfeeding",
        "brief_summary": "This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 \u03bcg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 \u03bcg in a population with COPD and elevated cardiopulmonary risk.",
        "NCTID": "NCT06283966"
    },
    "NCT04302272": {
        "brief_title": "STRIVE Post-Market Registry Study",
        "phase": "No Phase",
        "drugs": [],
        "drugs_list": "",
        "diseases": [
            "Emphysema"
        ],
        "diseases_list": "Emphysema",
        "enrollment": 150,
        "inclusion_criteria": "1. Adult patients with shortness of breath and hyperinflation associated with severe emphysema and evidence of low collateral ventilation.\n2. Subjects must understand and voluntarily sign an informed consent form.",
        "exclusion_criteria": "1. Subjects who are not appropriate for SVS therapy based upon the US FDA-approved IFU requirements.\n2. Subjects who were withdrawn from this study for any reason will not be allowed to re-enroll.\n3. Subjects who have incomplete screening or baseline data.",
        "brief_summary": "This is a single-arm, prospective, multi-center, Registry study to evaluate the long-term safety and effectiveness of the Spiration Valve System (SVS) for the treatment of severe emphysema in a post-market setting.",
        "NCTID": "NCT04302272"
    },
    "NCT06122077": {
        "brief_title": "Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening",
        "phase": "No Phase",
        "drugs": [],
        "drugs_list": "",
        "diseases": [
            "Lung Cancer Diagnosis"
        ],
        "diseases_list": "Lung Cancer Diagnosis",
        "enrollment": 20000,
        "inclusion_criteria": "1. Age 50 years or older within 30 days of enrollment\n2. Current or former smokers with a cumulative smoking history of \u2265 20 pack-year\n3. Able to comprehend and willing to sign and date the informed consent and HIPAA authorization documents",
        "exclusion_criteria": "1. Any active therapy for cancer, including but not limited to surgery, chemotherapy, biologic therapy, immunotherapy, and/or radiation therapy at the time of enrollment\n2. History of any malignancy within prior 5 years of enrollment (except for non- melanoma skin cancer)\n3. History of organ, tissue, and bone marrow transplantation\n4. Screened for lung cancer or having chest CT scan 12 months before enrollment\n5. Having signs and symptoms of lung cancer such as hemoptysis, superior vena cava syndrome, Cushing syndrome, and Pancoast syndrome\n6. Received a blood transfusion in the 30 days preceding enrollment\n7. Known to be pregnant\n8. Participated or currently participating in another Freenome-sponsored clinical study\n9. Participated or currently participating in a clinical research study in which an experimental medication has been administered during the 60 days preceding enrollment\n10. Any condition that in the opinion of the Investigator should not be enrolled in the study",
        "brief_summary": "The PROACT LUNG study is a prospective multi-center observational study to validate a blood-based test for the early detection of lung cancer by collecting blood samples from high-risk participants who will undergo a routine, standard-of-care screening Low-Dose Computed Tomography (LDCT).",
        "NCTID": "NCT06122077"
    }
}